Cogent Biosciences (COGT) Expected to Announce Quarterly Earnings on Tuesday

Cogent Biosciences (NASDAQ:COGT) is anticipated to announce its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect the company to post earnings of ($0.5550) per share and revenue of $0.0010 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Wednesday, August 5, 2026 at 12:30 PM ET.

Cogent Biosciences (NASDAQ:COGT) last posted its quarterly earnings data on Tuesday, May 5th. The technology company reported ($0.53) EPS for the quarter, meeting analysts’ consensus estimates of ($0.53). On average, analysts expect Cogent Biosciences to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Cogent Biosciences Stock Performance

Shares of COGT opened at $38.93 on Friday. Cogent Biosciences has a one year low of $10.38 and a one year high of $43.73. The company has a 50-day moving average of $36.66 and a two-hundred day moving average of $36.51. The stock has a market cap of $6.65 billion, a price-to-earnings ratio of -17.94 and a beta of 0.34. The company has a debt-to-equity ratio of 0.41, a current ratio of 15.14 and a quick ratio of 15.14.

Hedge Funds Weigh In On Cogent Biosciences

Institutional investors and hedge funds have recently bought and sold shares of the business. Deerfield Management Company L.P. lifted its position in Cogent Biosciences by 242.9% in the 3rd quarter. Deerfield Management Company L.P. now owns 9,053,118 shares of the technology company’s stock worth $130,003,000 after buying an additional 6,412,903 shares in the last quarter. RTW Investments LP boosted its stake in shares of Cogent Biosciences by 119.0% during the 4th quarter. RTW Investments LP now owns 7,592,241 shares of the technology company’s stock valued at $269,676,000 after buying an additional 4,124,755 shares during the period. Balyasny Asset Management L.P. purchased a new position in shares of Cogent Biosciences during the 3rd quarter valued at $38,348,000. Price T Rowe Associates Inc. MD grew its holdings in shares of Cogent Biosciences by 2,758.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,564,062 shares of the technology company’s stock valued at $91,076,000 after acquiring an additional 2,474,346 shares in the last quarter. Finally, Wellington Management Group LLP grew its holdings in shares of Cogent Biosciences by 566.6% during the 4th quarter. Wellington Management Group LLP now owns 2,712,336 shares of the technology company’s stock valued at $96,342,000 after acquiring an additional 2,305,437 shares in the last quarter.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on COGT shares. HC Wainwright boosted their price target on shares of Cogent Biosciences to $55.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cogent Biosciences in a research note on Wednesday, July 8th. Finally, Wedbush reiterated an “outperform” rating and set a $55.00 price objective on shares of Cogent Biosciences in a research report on Friday, May 29th. Two research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $45.90.

About Cogent Biosciences

Cogent Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that modulate the tumor microenvironment. The company’s research centers on targeting colony-stimulating factor 1 receptor (CSF1R), a key regulator of tumor-associated macrophages that can promote tumor growth and immune evasion. By selectively inhibiting CSF1R, Cogent Biosciences aims to restore immune surveillance and enhance the efficacy of existing cancer treatments.

The company’s lead asset is an orally bioavailable CSF1R inhibitor that has advanced into early-stage clinical trials for various solid tumors.